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Non-invasive Imaging of Idiopathic 
Pulmonary Fibrosis Using Cathepsin 
Protease Probes
Nimali P. Withana1,*, Xiaowei Ma2,*, Helen M. McGuire3, Martijn Verdoes1,†, Wouter A. van 
der Linden1, Leslie O. Ofori1, Ruiping Zhang2, Hao Li4, Laura E. Sanman4, Ke Wei5, 
Shaobo Yao6, Peilin Wu6, Fang Li6, Hui Huang7, Zuojun Xu7, Paul J. Wolters8, Glenn D. Rosen5, 
Harold R. Collard8, Zhaohui Zhu6, Zhen Cheng2 & Matthew Bogyo1,2,3
Idiopathic pulmonary fibrosis (IPF) is a lethal, chronic, progressive disease characterized by formation 
of scar tissue within the lungs. Because it is a disease of unknown etiology, it is difficult to diagnose, 
to predict disease course and to devise treatment strategies. Recent evidence suggests that activated 
macrophages play key roles in the pathology of IPF. Therefore, imaging probes that specifically 
recognize these pools of activated immune cells could provide valuable information about how these 
cells contribute to the pathobiology of the disease. Here we demonstrate that cysteine cathepsin-
targeted imaging probes can be used to monitor the contribution of macrophages to fibrotic disease 
progression in the bleomycin-induced murine model of pulmonary fibrosis. Furthermore, we show 
that the probes highlight regions of macrophage involvement in fibrosis in human biopsy tissues 
from IPF patients. Finally, we present first-in-human results demonstrating non-invasive imaging of 
active cathepsins in fibrotic lesions of patients with IPF. Together, our findings validate small molecule 
cysteine cathepsin probes for clinical PET imaging and suggest that they have the potential to be used 
to generate mechanistically-informative molecular information regarding cellular drivers of IPF disease 
severity and progression.
Pulmonary fibrosis is a process in which fibrotic lesions form in the lung resulting in scarring and progressive 
morbidity (physiological restriction and impaired oxygen diffusion). Fibrotic damage is the endpoint of many 
disorders of the lung including the idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, col-
lagen vascular diseases with lung involvement, and chronic lung infections1. Of these conditions involving lung 
fibrosis, Idiopathic Pulmonary Fibrosis (IPF) is considered the archetype. IPF is a progressive and fatal lung 
disease of unknown cause. Current estimates of disease incidence are 40–50 per 100,000 and include approxi-
mately 125,000 cases in the United States2,3. Most patients are 50 to 70 years old, but patients with familial IPF 
tend to present earlier3–5. Patients are usually symptomatic for 6 to 24 months before diagnosis but often present 
with advanced fibrotic disease. Despite therapy, IPF has a median survival of only 4–5 years4,5. There are two 
recently approved therapies for IPF in the United States, but neither has been shown to stop disease progression 
or improve survival6,7. The lack of curative treatments is largely due to the unique pathogenesis of IPF and our 
lack of understanding of the factors that regulate disease course.
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There is recent strong evidence to suggest that immune cells such as monocytes and macrophages play impor-
tant roles in the overall disease pathology. While it is likely that repeated cycles of lung epithelial injury followed 
by accumulation and activation of fibroblasts in IPF are significant drivers of disease pathogenesis, recent studies 
suggest that activated macrophages are also likely key contributors8. For example, injured type II alveolar epithe-
lial cells produce cytokines leading to accumulation of activated macrophages at fibroblastic foci9. This activated 
macrophage population also produces transforming growth factor beta (TGF-β ) and CCL18, potent pro-fibrotic 
cytokines that are key mediators of lung fibrosis. CCL18 is produced preferentially by alternatively activated 
macrophages and high serum levels of this cytokine in IPF patients is associated with a higher incidence of dis-
ease progression10. Serum CCL18 has also been shown to predict lung disease worsening in systemic sclerosis11. 
Finally, a recent study found that surfactant protein D (SP-D) deficiency leads to macrophage infiltration and the 
production of the pro-fibrotic cytokines, TGF- β and platelet derived growth factor AA (PDGF-AA) in the BLM 
lung fibrosis model12.
Cysteine cathepsins are a group of proteases with elastinolytic and collagenolytic activities that are involved in 
various aspects of ECM remodeling13. Of the 11 members of this cysteine protease family, cathepsins B, L and S 
contribute to the degradation of several types of collagen and elastin in the extracellular space14. These proteases 
are also secreted into the extracellular space and the bronchoalveolar lavage (BAL) fluid in pulmonary disorders15. 
Furthermore, the activities of these proteases in lung tissue homogenates and activated alveolar macrophages are 
elevated during tissue regeneration and remodeling16. Because cathepsins are highly expressed in activated mac-
rophages17,18, they are potential diagnostic and therapeutic targets in IPF disease pathogenesis.
Reagents that can detect activated forms of the cysteine cathepsins are valuable tools for highlighting sites 
of disease pathology involving macrophage infiltration19–21. We have developed small molecule optical imaging 
probes that specifically report on the activity of cysteine cathepsins22. These probes can be used to image popula-
tions of activated macrophages that have high expression of the cysteine cathepsins. We have also demonstrated 
that positron emission tomography (PET) versions of cathepsin probes can be used for non-invasive imaging of 
cancer margins as the result of the high content of activated macrophages within solid tumours23.
In this study, we utilize the bleomycin-induced murine model of lung fibrosis, tissues from human clini-
cal samples and first-in-human imaging studies to demonstrate the value of non-invasive imaging of cysteine 
cathepsin activity to understand the role of these proteases in IPF disease pathobiology. Our results confirmed 
an increased uptake of the imaging agent in fibrotic lesions suggesting a role for activated macrophages in the 
pathobiology of the human disease.
Results
Generation of molecular probes for dual optical/PET imaging of activated macrophages. We 
have developed several classes of activity based probes (ABPs) targeting cysteine cathepsins18–20,22,24. In particu-
lar, the probe GB123, containing a 2,6-dimethylbenzoic acid-derived acyloxymethyl ketone (AOMK) electro-
phile has been validated in numerous in vivo optical imaging applications and was shown to target cathepsins 
B, S and L19,25–27. Recently, we demonstrated that a cathepsin ABP containing a phenoxymethyl ketone (PMK) 
electrophile, BMV109, has enhanced in vivo properties and broad reactivity towards cathepsins X, B, S and L22 
and can be used for imaging of tumour margins in vivo21. Based on these highly successful probes, we designed 
a dual labelled ABP, BMV101, that could be used for both optical and PET/CT imaging applications (Fig. 1). 
This new probe contains a Cy5 near infrared (NIR) fluorophore for optical detection and a NOTA chelator for 
labelling with 64Cu, Al18F or 68Ga for PET/CT imaging applications. Importantly, the new probe, BMV101, per-
formed nearly identically to BMV109 and GB123, with respect to labelling of cathepsins B, S and L in intact cells 
(Supplementary Fig. S1).
Imaging disease progression in the bleomycin-induced model of lung fibrosis. We first per-
formed a study with the optimized optical probe, BMV109, to determine if cysteine cathepsins could be used 
as markers of pulmonary fibrosis in the lung. Bleomycin has been used extensively to model pulmonary fibrosis 
in rodents, with direct administration into the lungs being highly effective in eliciting fibrosis28. We assessed the 
Figure 1. Structures of the activity based probes (ABPs) GB123, BMV109 and BMV101. 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:19755 | DOI: 10.1038/srep19755
extent of probe accumulation in the lungs, focusing on a time course between 7 and 14 days (Fig. 2A), a time 
period in which immune cell infiltration and initiation of fibrosis takes place29. Disease burden was evident in the 
bleomycin treated group at both time-points after bleomycin administration as measured by total body weight 
loss and increased lung weight (Supplementary Fig. S2A). Lung tissue at day 7 and at day 14 showed histological 
evidence of pulmonary fibrosis, at both time points and was greatest at day 14 (Supplementary Fig. S2B). We were 
also able to confirm the onset of fibrosis by increased lung collagen content at Day 14 (Supplementary Fig. S2B).
For optical imaging studies, we injected mice with the BMV109 probe via tail vein at each time-point and 
non-invasively quantified Cy5 fluorescence in the lung region 4 hours after probe injection (Fig. 2A). At Day 7, 
bleomycin-treated mice showed significantly higher fluorescence signal in the lungs when compared to the saline 
controls. Signal intensity further increased at Day 14. Probe signal was also detected in the liver and kidney of 
both groups due to clearance of the probe. We found that levels of fluorescence in the excised lungs directly corre-
lated with the levels observed using non-invasive optical imaging methods (Fig. 2B). Subsequent analysis of lung 
tissues by SDS-PAGE confirmed that the primary targets of the probe in these tissues were cathepsins X, B, S and 
L, and that levels of labelling of these targets correlated with the extent of disease burden and intensity of signals 
observed by non-invasive imaging (Fig. 2C).
Immune cell contribution to disease progression in the bleomycin lung fibrosis model. Brief 
exposure to bleomycin causes epithelial cell apoptosis, activating an inflammatory wound-healing response, ulti-
mately leading to pulmonary fibrosis. We sought to further characterize the immune cell infiltrate and define 
the distinct cell populations labelled by BMV109 during bleomycin-induced fibrosis. After bleomycin exposure, 
probe labelling in the lung co-localized specifically with the macrophage marker CD68, with the intensity of the 
probe signal increasing from Day 7 to Day 14 as disease burden increased (Supplementary Fig. S2C). Flow cyto-
metric analysis allowed us to further characterize the population of infiltrating leukocytes in diseased lung, with 
particular focus on the probe labelled macrophage population. Bronchoalveolar lavage (BAL) fluid from mice 
post bleomycin exposure had significantly more leukocytes compared to saline controls. Macrophage populations 
dominated the immune infiltrate across all groups tested. Neutrophils were enriched in control and bleomycin 
treated mice on day 7, but declined by day 14. Day 14 was marked by a significant increase in other immune cells, 
consistent with lymphocytes (by forward and side scatter profiles), corresponding to increased inflammation 
(Supplementary Fig. S2D). BMV109 staining was highly enriched in the F4/80+ /CD11c+ macrophage popula-
tions, with the intensity of probe per cell (mean fluorescence intensity, MFI) greater in bleomycin-treated mice 
at both time points, indicating increased cathepsin activity in these cells (Fig. 3A). Intracellular flow cytometric 
analysis revealed an increased macrophage expression of pro-inflammatory IL-12 at day 7, in BAL fluid that was 
not sustained at day 14 (Fig. 3B). Furthermore, a shift to the pro-fibrotic response was evident, with increased 
M2-like macrophage associated IL-10 production and CD206 expression.
Coordinate or discordant regulation of several cytokines and chemokines are reported to correlate with IPF 
disease progression30. To determine if these markers mimicked levels observed in the human condition, we per-
formed multiplexed cytokine profiling of plasma from bleomycin-treated mice at Day 7 and Day 14 (Fig. 3C). 
We found that the cytokines IL-1β , IL-10 and IL-2 increased from Day 7 to Day 14. Similarly, a downstream 
target of IL-1β , IL-17 increased from the early to late stages of the disease. This cytokine plays a role in mediating 
the fibrotic response31. Markers of the Th2, pro-fibrotic immune response, IL-4 and IL-5, were low at Day 7 but 
increased with disease progression at Day 14. Overall, the changes in the levels of cytokines and chemokines upon 
induction of fibrosis in the mouse model were consistent with those observed in human IPF samples32,33.
PET/CT and optical imaging of cathepsin activity in the bleomycin lung fibrosis model. We 
next applied 64Cu-labeled BMV101 to the bleomycin model. We chose this radionuclide because it has a relatively 
Figure 2. Application of the ABP BMV109 to image active cathepsins in the bleomycin mouse model of 
lung fibrosis. (A) Non-invasive optical images of mice treated with saline or bleomycin and (B) corresponding 
ex vivo fluorescence intensity from excised lungs for the different treatment groups. Error bars indicate 
mean ± SEM., n = 5 mice per group. **p < 0.01 by t-test. (C) SDS-PAGE analysis followed by flatbed laser 
scanning to detect probe labelled cathepsins in lung tissue lysates from mice from the different treatment 
groups. Lung lysate samples are for each individual mouse where n = 5 in each group. Total cathepsin labelling 
intensity was measured using imageJ and plotted for each group. ****p < 0.0001 by t-test. For completed image 
of uncropped gel see supplemental information files.
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long half-life (12.7 hrs) and therefore could be used for imaging at extended time points (i.e. 24 hr) after probe 
injection. We performed optical/PET-CT imaging studies with 64Cu-BMV101 at the same time points post bleo-
mycin treatment that we used for the optical probe except we added a Day 21 time point to cover later stage pro-
gression of the disease (Fig. 4 and Supplementary Fig. S2,3). Again, disease burden was evident in the bleomycin 
treated groups as measured by total body weight loss and increased lung weight (Supplementary Fig. S3A). We 
performed small animal PET-CT imaging and observed increased probe signal at Day 7 and Day 14 in lungs of 
bleomycin treated mice relative to control mice (Fig. 4A). Furthermore, this level increased from Day 7 to Day 
14 as macrophage infiltration increased. At Day 21, we observed reduced probe signal in the bleomycin treated 
lungs, likely due to the fact that in the rodent fibrosis model, immune cell infiltration decreases over time34. 
Biodistribution studies confirmed that the probe accumulated in the blood, liver, heart and kidney, but showed 
the most significant increased accumulation in the lungs of the bleomycin treated mice compared to controls 
(Supplementary Fig. S5A). Specific probe uptake into lungs was confirmed by quantification and comparison 
of lung to liver and lung to muscle ratios at each time-point (Supplementary Fig. S5B). Since the probe has dual 
optical and PET labels, we were also able to visualize probe signals in the lungs by non-invasive optical imaging 
and by ex vivo imaging of the lungs (Fig. S4). Day 7 and Day 14 mice with lung fibrosis showed significantly 
higher optical probe signal in the lung when compared to the controls by both non-invasive and ex vivo imaging 
(Supplementary Fig. S4), consistent with the PET-CT results. Subsequent analysis of lung tissues by SDS-PAGE 
revealed increased levels of active cathepsins, dominated by cathepsin B and S, in the bleomycin-induced lung 
samples relative to the controls (Fig. 4B). Non-invasive and ex vivo analysis of Day 21 samples showed decreased 
lung cathepsin expression, which correlated with a decrease in macrophage infiltration (Supplementary Fig. S4). 
Figure 3. Immunologic profiling during progression of pulmonary fibrosis. (A) Analysis of Day 7 and 14 
BAL fluid from mice to monitor activated macrophages during disease progression. Samples were analysed by 
FACS for the indicated immune cell markers. Error bars indicate mean ± SD., Day 7 (saline n = 5; bleomycin 
n = 7) and Day 14 (saline n = 8; bleomycin n = 15). *p < 0.05, **p < 0.01, ***p < 0.005 by Mann-Whitney test. 
(B) Intracellular flow cytometric analysis of macrophages expressing IL-10, IL-12 and CD206, measured in BAL 
fluid of bleomycin treated mice on days 7 and 14. Error bars indicate mean ± SD., Day 7 (saline n = 5; bleomycin 
n = 10) and Day 14 (saline n = 8; bleomycin n = 15). ***p < 0.005 by Mann-Whitney test. (C) Luminex cytokine 
profiling of plasma from Day 7 (n = 10) and Day 14 (n = 15) mice compared to control mice, pooled from Day 
7 (n = 10) and Day 14 (n = 10). Colours represent level of expression of each of the indicated cytokines with 
red being highly expressed and blue being lowly expressed (scale bar shows z-score, standardized across each 
cytokine, where mean = 0, and standard deviation is 1). Several of the key cytokines linked to IPF in humans are 
highlighted with black boxes.
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Figure 4. Application of the ABP 64Cu-BMV101 as a dual optical/PET imaging probe. (A) Non-invasive 
PET/CT scans of mice treated with saline or bleomycin at Day 7, Day 14 and Day 21. Coronal (left), transaxial 
(top right) and sagittal (bottom right) images are shown for representative mice from saline or bleomycin treated 
groups at the indicated time points. Corresponding quantification of PET/CT intensity from lungs of all mice 
at Day 7, Day 14 and Day 21 in the different treatment groups are shown alongside PET/CT images. Error bars 
indicate mean ± SEM., Day 7 (saline n = 3; bleomycin n = 5), Day 14 (saline n = 3; bleomycin n = 7) and Day 21 
(saline n = 3; bleomycin n = 8). *p < 0.05, ****p < 0.0001 by t-test. (B) SDS-PAGE analysis followed by flatbed laser 
scanning to detect probe labeled cathepsins in lung tissue lysates from mice from the different treatment groups 
(saline n = 3 and bleomycin n = 5). Total cathepsin labeling intensity was measured using imageJ and plotted for 
each group. Error bars indicate mean ± SEM., **p < 0.005 by t-test. The identity of specific cysteine cathepsins is 
indicated for the SDS-PAGE images. For full uncut gel images see supplementary information files.
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This was further confirmed by histology and immunofluorescence analysis (Supplementary Fig. S3B and S3C). 
Taken together, these results confirm that the non-invasive PET imaging signals correlated with the onset of fibro-
sis at days 7 and 14 and correlated with the presence of activated macrophages in the lungs.
Topical labelling of human lung tissues from patients with idiopathic pulmonary fibrosis. We 
have recently shown that small molecule ABPs can be used to topically label active cathepsins in excised tis-
sues21,35. We therefore topically labelled sectioned frozen tissue samples from IPF patients undergoing surgical 
lung biopsy or lung transplantation with the optical probe BMV109 (Fig. 5, S6). We also co-stained the tissues 
with the macrophage marker (CD68). These data confirmed labelling of macrophages that are actively expressing 
cysteine cathepsins and that the signals for active cathepsins were specifically found at sites of fibrotic lesions. 
Thus, cathepsins may be ideal biomarkers for monitoring of disease activity in IPF.
Application of an activity based PET imaging probe in patients with idiopathic pulmonary 
fibrosis. We chose to use 68Ga as our radionuclide for first-in-human trials since it has been used extensively 
in clinical imaging and is relatively easy to generate. However, it has a short half-life (68 min) and therefore 
required imaging within the first few hours of probe administration. Prior to translation into studies in humans, 
we tested the effectiveness of 68Ga-BMV101 in the bleomycin lung fibrosis model (Supplementary Fig. S7). These 
results confirmed that it produced similar results to 64Cu-BMV101, with increased probe signal observed in lungs 
of bleomycin treated mice.
For the human clinical studies, we recruited six subjects and three controls with healthy lung function 
(Supplementary Table S1). Of the six patients with lung fibrosis, three were confirmed as having idiopathic pul-
monary fibrosis by multidisciplinary review according to ATS/ERS/JRS/ALAT criteria3 while the remaining three 
were unclassifiable pulmonary fibrosis. Subjects were between the age of 51 and 76, were predominantly former 
smokers, and had varying levels of physiological impairment. The 68Ga-BMV101 PET-CT probe was injected 
intravenously and images were collected at 2.5 hours post probe administration. These data demonstrated that 
the probe showed increased accumulation in regions of fibrosis in the lungs of the three patients with IPF, with 
no significant increase in probe accumulation in the unclassified fibrosis patients relative to the normal lung 
(Fig. 6). Importantly, there was also no significant increase in probe accumulation in the liver of the patients 
with IPF or lung fibrosis compared to the healthy controls. Overall, the ratio of probe signals in lung compared 
to muscle were high (4.36 for IPF patients and 1.37 for normal controls; Table S) with more than 3 times greater 
accumulation of the probe in lungs of patients with IPF. Taken together, these results confirm that the probe is a 
viable PET contrast agent that accumulates in regions of lung fibrosis in patients with IPF. The data also suggest 
that the bleomycin-induced fibrosis in the mouse correlates with the pathobiology of human patients with IPF, 
and suggest that macrophages may be important regulators of disease progression in humans.
Discussion
Concerted efforts have recently been made to develop new technologies for early disease monitoring to facilitate 
diagnosis and therapeutic intervention for IPF. Optical and PET imaging has great promise and potential appli-
cation in this respect22. Activity based probes (ABPs) generate a signal in response to covalent modification of a 
specific enzymatic target and are therefore useful as contrast agents for imaging. Cysteine cathepsins expressed 
in antigen presenting cells such as macrophages, are promising biomarkers of macrophage activation, with 
Figure 5. Topical staining of human tissues with BMV109. Representative images from IPF (A) and healthy 
control (B) human lungs that were labelled with the optical probe BMV109 (red) and co-stained with the 
marker for macrophages, CD68 (green). Samples were tile scanned at high resolution to generate full images. 
Insets show regions of interest at higher magnification. White scale bars on zoom images are 10 μ m. Yellow scale 
bars on full tiled images represent 1 mm. Additional patient sample data in Supplementary Fig. S6.
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cathepsins B and S in particular, implicated in lung disease36,37. Recent evidence suggests that these immune cells 
play important roles in the overall disease pathology of IPF8. For these reasons, we hypothesized that ABPs that 
target cysteine cathepsins would specifically highlight infiltrating macrophages that contribute to the pathobiol-
ogy of IPF, and that these ABPs could have broad value for non-invasive monitoring of disease activity. We further 
expect that these probes might also allow for early diagnosis with increased sensitivity compared to HRCT38. 
Currently, there have been no reported non-invasive imaging clinical studies of any contrast agent in patients 
with IPF.
Here we describe the application of cysteine cathepsin activity-based probes to the rodent model of lung fibro-
sis and in human IPF lungs. The relevance of the bleomycin mouse model to IPF has been questioned because 
it is thought to mimic acute lung injury followed by scar formation, rather than abnormal wound healing or 
progressive fibroproliferation. Also, with the direct administration of bleomycin to the lungs, the initial phase of 
bleomycin-induced injury is primarily pro-inflammatory with an influx of neutrophils and mononuclear infil-
trate30, which has not been observed in IPF. Although the bleomycin model has been criticized for its speed of dis-
ease onset and durability of fibrosis, it remains a robust, well-established, reproducible model of lung fibrosis that 
can reveal potential mechanisms underlying the human disease30,31. Our results presented here further confirm 
that this model produces many of the same hallmarks of human IPF disease pathology, especially with respect 
to the activation and accumulation of macrophages and the production of hallmark cytokines. Specifically, our 
data shows that IL-1β , IL-10, IL-2, were key cytokines that increased from Day 7 to Day 14 in the murine model, 
consistent with what has been observed in primary patient samples9. Thus, for the purposes of validating imaging 
probes that aim to report on relevant aspects of the immune program in IPF disease pathogenesis, this model 
remains highly valuable.
The first-in-human results for the 68Ga-labeled probe provide strong support for the notion that activated 
macrophages are regulators of the pathobiology of IPF disease progression. Our clinical results mirror our find-
ings in the bleomycin mouse model of fibrosis where we see accumulation of macrophages with high cathepsin 
activity both at early onset and once the fibrotic process has been fully established. This again suggests that the 
bleomycin model proves valuable information that is relevant to the human disease, with respect to immune cell 
involvement. Furthermore, the fact that we do not see significant probe accumulation in patients with unclassified 
lung fibrosis provides some support for the potential to use cathepsin probes to stratify patients with IPF such 
that they can be followed and eventually treated with new therapies that are currently in clinical trials. We believe 
that additional follow up imaging trials on a larger number of patients, coupled with collection of BAL fluids for 
analysis of levels of activated macrophages in the lungs, will allow a more clear understanding of the importance 
of activated macrophage populations with respect to IPF disease severity, progression and response to treatment.
Figure 6. First-in-human application of imaging probe 68Ga-BMV101. (A) Representative scans of patients 
with idiopathic pulmonary fibrosis (IPF) and unclassifiable pulmonary fibrosis (Fibrosis) compared to healthy 
controls. Left hand images show axial CT image in the lung window. Right hand images show axial fused 
PET/CT of the same section. (B) Plot of quantitative SUVmax values for lung and liver from controls, IPF and 
fibrosis patients. Error bars indicate mean ± SEM., *p < 0.05 by Wilcoxon Mann Whitney U test.
www.nature.com/scientificreports/
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While our initial results with the dual optical/PET probe are promising both in the preclinical animal models 
and in human patients with IPF, we noted that the overall signal to noise ratios were rather poor (see Tables S2-4). 
Specifically, when comparing lung to liver signals we obtained values below a value of 1. This is likely do to high 
baseline cathepsin activity in the liver and also relatively high blood pooling of the probe. This explanation was 
further supported by the fact that lung to muscle ratios were substantially higher. We also observed high PET 
signals in the blood (Fig. S5). This blood pooling effect is likely due to the highly hydrophobic/aromatic nature 
of the probe. Therefore, we are currently working to identify a more effective probe backbone structure that is 
still recognized by the protease targets but that is more highly hydrophilic and charged. This should both help 
to reduce the blood retention of the probe and also increase solubility and formulation properties which should 
facilitate further clinical studies.
In conclusion, we report the development of a new bimodal optical/PET probe and its use as an imaging 
agent for monitoring the pathobiology of IPF. Having a dual label on the probe allows for initial PET imaging and 
subsequent optical analysis by in vivo and in vitro methods. Importantly, the use of a PET/optical probe, for the 
first time, provided a means to non-invasively image regions of lung fibrosis and correlate findings in the mouse 
model of fibrosis with human IPF disease. We find that the early stages of fibrosis in the mouse model involve 
macrophage responses that peak early in the onset of fibrosis (i.e. day 15). In humans, we find that the probe 
accumulates in regions of fibrosis that are more likely late events that may involve persistent, unresolved injury 
around established fibrotic lesions. Thus, our probe could be highly valuable for assessing overall disease activity, 
even in patients who have advanced disease. Furthermore, these results suggest that our probe has the potential 
to be applied in the clinic to facilitate study of the cellular and molecular events that drive IPF pathology. They are 
also likely to be useful preclinical and clinical tools for other diseases that involve contributions from activated 
immune cells that express the cysteine cathepsins.
Materials and Methods
Synthesis of Probes. Details of the probe synthesis, radiolabeling and compound characterization can be 
found in the supplemental methods section.
Animals and Model Induction. Female C57BL/6J mice weighing 20–25 g were purchased from Jackson 
Laboratories (Bar Harbor, ME). To induce pulmonary fibrosis, mice were treated on day 0 with 1.5 unit/kg body 
weight of bleomycin (MP Biomedicals LLC) by endotracheal instillation as previously described39; control ani-
mals received sterile saline. At the indicated times (day 7 and day 21), the probe BMV109 was injected at a dose 
of 10 nmol in 10% DMSO/PBS, 4 hours prior to harvest, and mice were imaged non-invasively using the IVIS 100 
system. Animals were sacrificed under isoflurane anesthesia and BAL fluid extracted as previously describe40. 
Lungs were then removed, imaged ex vivo using an FMT system. Samples of lung tissue and cells were collected 
for further analysis, as described below. A total of 10 animals were used for each time point, divided equally 
between control and bleomycin-treated groups and not randomized. This sample size was chosen based on 
knowledge that some animals may not survive the course of the experiment and that a cohort of at least 3 animals 
per group are required in order to get statistical significance in the results. Investigators conducting the trial were 
not blinded as to what groups were being studied unless otherwise stated. All mouse experiments were approved 
by the Stanford Administration Panel on Laboratory Animal Care and strictly followed their specific guidelines.
Murine PET In Vivo Imaging. Mice were intravenous injected with 100 μ Ci of 64Cu-BMV101 and imaged 
after 1 h, 2 h, and 4 h by using Inveon small-animal PET/CT (Siemens). Briefly, a CT anatomic image scan 
was acquired (80 kV, 500 μ A) with a pixel size of approximately 0.1 mm. After CT imaging, whole-body PET 
imaging was performed with 5 min static scan. The PET images were reconstructed using the ordered-subsets 
expectation maximization 3-dimensional algorithm based on CT attenuation and analyzed using the Inveon 
Research Workplace (IRW) software (Siemens). PET voxel size was 0.796 × 0.861 × 0.861 mm, for a total of 
128 × 128 × 159 voxels. After the 4 h PET/CT imaging, the mouse was injected with 100 μ L BMV101 (10 mM) 
and imaged for fluorescence signal by IVIS200 (Perkin Elmer) at 1 h later. Then PET/CT quantify assay was per-
formed, and tissue radioactivity was calculated and expressed as decay-corrected percentage injected dose per 
gram of tissue (%ID/g). Investigators conducting the trial were blinded as to what groups were being imaged.
Tissue and cell labeling and analysis. Details of the tissue and cell preparation, probe labeling and anal-
ysis by microscopy and flow cytometry can be found in the supplementary methods section.
Patient Recruitment. This study was approved by the Institute Review Boards of Peking Union Medical 
College Hospital and conducted from December 2014 to April 2015 and was carried out in accordance with the 
approved guidelines. Nine patients were enrolled in this study after obtaining written informed consent. The 
subjects were deemed to have IPF or IPF-related condition based on their clinical history, physical examination, 
standard blood and urine tests, CT and electrocardiogram. Subjects were contacted by telephone approximately 
24 h after 68Ga-BMV101 administration, for adverse events monitoring. Subjects included were between the ages 
of 35 and 80 and had fibrotic interstitial lung disease as defined by the presence of reticulation, traction bron-
chiectasis and honeycombing on high-resolution computed tomography (HRCT) imaging of the chest. Controls 
without lung disease were recruited from patients undergoing PET-CT scans for non-pulmonary indications. 
Exclusion criteria included pregnancy, lactation, the presence of co-existing emphysema on HRCT, and impaired 
renal or liver function. Human subjects research was approved by the ethics review committees of Stanford 
University Medical Center (Stanford, CA, United States) and Peking Union Medical College (Beijing, China), 
and all participants provided informed consent.
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Statistical Analysis of Data. Statistics were performed using the data analysis package within GraphPad 
Prism 6.0 for Windows (GraphPad Software, San Diego, CA, USA). For the human studies, SUVmax values from 
subjects and controls were compared using the Wilcoxon Mann Whitney U test to account for non-normally dis-
tributed data. Statistical significance was defined as a p value < 0.05. Unless otherwise stated, tests comparing two 
means are a Student’s t-test, with equal variance assumed. Error bars indicate standard error of the mean (SEM) 
unless otherwise stated.
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